Macrophage inhibitory cytokine 1 (MIC-1/GDF15) as a novel diagnostic serum biomarker in pancreatic ductal adenocarcinoma
详细信息 查看全文
- 作者：Xiaobing Wang (5)
Yanfen Li (5)
Haimei Tian (5)
Jun Qi (6)
Mo Li (5)
Chao Fu (7)
Fan Wu (8)
Yi Wang (9)
Dongwan Cheng (10)
Wenya Zhao (5)
Chao Zhang (5)
Teng Wang (5)
Jianyu Rao (5)
Wei Zhang (5)
5. Medical Center for Tumor Detection ; Cancer Institute and Hospital ; Chinese Academy of Medical Sciences and Peking Union Medical College ; Beijing ; 100021 ; PR China
6. Laboratory of Clinical Biochemistry ; Cancer Institute and Hospital ; Chinese Academy of Medical Sciences and Peking Union Medical College ; Beijing ; 100021 ; PR China
7. Laboratory of Clinical Biochemistry ; Xi鈥檃n NO 4 hospital ; Xi鈥檃n ; 710004 ; PR China
8. Department of Abdominal Surgical Oncology ; Cancer Institute and Hospital ; Chinese Academy of Medical Sciences and Peking Union Medical College ; Beijing ; 100021 ; PR China
9. Department of VIP ; Cancer Institute and Hospital ; Chinese Academy of Medical Sciences and Peking Union Medical College ; Beijing ; 100021 ; PR China
10. National Laboratory of Biomacromolecules ; Institute of Biophysics ; Chinese Academy of Sciences ; Beijing ; 100021 ; PR China - 刊名：BMC Cancer
- 出版年：2014
- 出版时间：December 2014
- 年：2014
- 卷：14
- 期：1
- 全文大小：891 KB
- 参考文献：1. Siegel, R, Naishadham, D, Jemal, A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: pp. 10-29 CrossRef
2. Mancuso, A, Calabro, F, Sternberg, CN (2006) Current therapies and advances in the treatment of pancreatic cancer. Crit Rev Oncol Hematol 58: pp. 231-241 CrossRef
3. Riall, TS, Nealon, WH, Goodwin, JS, Zhang, D, Kuo, YF, Townsend, CM, Freeman, JL (2006) Pancreatic cancer in the general population: Improvements in survival over the last decade. J Gastrointest Surg 10: pp. 1212-1223 CrossRef
4. Conlon, KC, Klimstra, DS, Brennan, MF (1996) Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann Surg 223: pp. 273-279 CrossRef
5. Li, D, Xie, K, Wolff, R, Abbruzzese, JL (2004) Pancreatic cancer. Lancet 363: pp. 1049-1057 CrossRef
6. Brand, RE, Nolen, BM, Zeh, HJ, Allen, PJ, Eloubeidi, MA, Goldberg, M, Elton, E, Arnoletti, JP, Christein, JD, Vickers, SM, Langmead, CJ, Landsittel, DP, Whitcomb, DC, Grizzle, WE, Lokshin, AE (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17: pp. 805-816 CrossRef
7. Goonetilleke, KS, Siriwardena, AK (2007) Systematic review of carbohydrate antigen (CA 19鈥?) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 33: pp. 266-270 CrossRef
8. Distler, M, Pilarsky, E, Kersting, S, Grutzmann, R (2013) Preoperative CEA and CA 19鈥? are prognostic markers for survival after curative resection for ductal adenocarcinoma of the pancreas - a retrospective tumor marker prognostic study. Int J Surg 11: pp. 1067-1072 CrossRef
9. Ni, XG, Bai, XF, Mao, YL, Shao, YF, Wu, JX, Shan, Y, Wang, CF, Wang, J, Tian, YT, Liu, QF, Xu, DK, Zhao, P (2005) The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31: pp. 164-169 CrossRef
10. Plebani, M, Basso, D, Navaglia, F, D鈥橝ngeli, F, Panozzo, MP, Del Giudice, G, Battistel, M, Meggiato, T, Del Favero, G (1995) Is CA242 really a new tumour marker for pancreatic adenocarcinoma?. Oncology 52: pp. 19-23 CrossRef
11. Bootcov, MR, Bauskin, AR, Valenzuela, SM, Moore, AG, Bansal, M, He, XY, Zhang, HP, Donnellan, M, Mahler, S, Pryor, K, Walsh, BJ, Nicholson, RC, Fairlie, WD, Por, SB, Robbins, JM, Breit, SN (1997) MIC-1, a novel macrophage inhibitory cytokine, is a divergent member of the TGF-beta superfamily. Proc Natl Acad Sci U S A 94: pp. 11514-11519 CrossRef
12. Paralkar, VM, Vail, AL, Grasser, WA, Brown, TA, Xu, H, Vukicevic, S, Ke, HZ, Qi, H, Owen, TA, Thompson, DD (1998) Cloning and characterization of a novel member of the transforming growth factor-beta/bone morphogenetic protein family. J Biol Chem 273: pp. 13760-13767 CrossRef
13. Boyle, GM, Pedley, J, Martyn, AC, Banducci, KJ, Strutton, GM, Brown, DA, Breit, SN, Parsons, PG (2009) Macrophage inhibitory cytokine-1 is overexpressed in malignant melanoma and is associated with tumorigenicity. J Invest Dermatol 129: pp. 383-391 CrossRef
14. Breit, SN, Johnen, H, Cook, AD, Tsai, VW, Mohammad, MG, Kuffner, T, Zhang, HP, Marquis, CP, Jiang, L, Lockwood, G, Lee-Ng, M, Husaini, Y, Wu, L, Hamilton, JA, Brown, DA (2011) The TGF-beta superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism. Growth Factors 29: pp. 187-195 CrossRef
15. Buckhaults, P, Rago, C, St Croix, B, Romans, KE, Saha, S, Zhang, L, Vogelstein, B, Kinzler, KW (2001) Secreted and cell surface genes expressed in benign and malignant colorectal tumors. Cancer Res 61: pp. 6996-7001
16. Hsiao, EC, Koniaris, LG, Zimmers-Koniaris, T, Sebald, SM, Huynh, TV, Lee, SJ (2000) Characterization of growth-differentiation factor 15, a transforming growth factor beta superfamily member induced following liver injury. Mol Cell Biol 20: pp. 3742-3751 CrossRef
17. Welsh, JB, Sapinoso, LM, Kern, SG, Brown, DA, Liu, T, Bauskin, AR, Ward, RL, Hawkins, NJ, Quinn, DI, Russell, PJ, Sutherland, RL, Breit, SN, Moskaluk, CA, Frierson, HF, Hampton, GM (2003) Large-scale delineation of secreted protein biomarkers overexpressed in cancer tissue and serum. Proc Natl Acad Sci U S A 100: pp. 3410-3415 CrossRef
18. Brown, DA, Ward, RL, Buckhaults, P, Liu, T, Romans, KE, Hawkins, NJ, Bauskin, AR, Kinzler, KW, Vogelstein, B, Breit, SN (2003) MIC-1 serum level and genotype: associations with progress and prognosis of colorectal carcinoma. Clin Cancer Res 9: pp. 2642-2650
19. Huh, SJ, Chung, CY, Sharma, A, Robertson, GP (2010) Macrophage inhibitory cytokine-1 regulates melanoma vascular development. Am J Pathol 176: pp. 2948-2957 CrossRef
20. Kim, KK, Lee, JJ, Yang, Y, You, KH, Lee, JH (2008) Macrophage inhibitory cytokine-1 activates AKT and ERK-1/2 via the transactivation of ErbB2 in human breast and gastric cancer cells. Carcinogenesis 29: pp. 704-712 CrossRef
21. Lee, DH, Yang, Y, Lee, SJ, Kim, KY, Koo, TH, Shin, SM, Song, KS, Lee, YH, Kim, YJ, Lee, JJ, Choi, I, Lee, JH (2003) Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system. Cancer Res 63: pp. 4648-4655
22. Li, PX, Wong, J, Ayed, A, Ngo, D, Brade, AM, Arrowsmith, C, Austin, RC, Klamut, HJ (2000) Placental transforming growth factor-beta is a downstream mediator of the growth arrest and apoptotic response of tumor cells to DNA damage and p53 overexpression. J Biol Chem 275: pp. 20127-20135 CrossRef
23. Liu, T, Bauskin, AR, Zaunders, J, Brown, DA, Pankhurst, S, Russell, PJ, Breit, SN (2003) Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Res 63: pp. 5034-5040
24. Selander, KS, Brown, DA, Sequeiros, GB, Hunter, M, Desmond, R, Parpala, T, Risteli, J, Breit, SN, Jukkola-Vuorinen, A (2007) Serum macrophage inhibitory cytokine-1 concentrations correlate with the presence of prostate cancer bone metastases. Cancer Epidemiol Biomarkers Prev 16: pp. 532-537 CrossRef
25. Senapati, S, Rachagani, S, Chaudhary, K, Johansson, SL, Singh, RK, Batra, SK (2010) Overexpression of macrophage inhibitory cytokine-1 induces metastasis of human prostate cancer cells through the FAK-RhoA signaling pathway. Oncogene 29: pp. 1293-1302 CrossRef
26. Yang, H, Choi, HJ, Park, SH, Kim, JS, Moon, Y (2009) Macrophage inhibitory cytokine-1 (MIC-1) and subsequent urokinase-type plasminogen activator mediate cell death responses by ribotoxic anisomycin in HCT-116 colon cancer cells. Biochem Pharmacol 78: pp. 1205-1213 CrossRef
27. Jutooru, I, Chadalapaka, G, Chintharlapalli, S, Papineni, S, Safe, S (2009) Induction of apoptosis and nonsteroidal anti-inflammatory drug-activated gene 1 in pancreatic cancer cells by a glycyrrhetinic acid derivative. Mol Carcinog 48: pp. 692-702 CrossRef
28. Mimeault, M, Batra, SK (2010) Divergent molecular mechanisms underlying the pleiotropic functions of macrophage inhibitory cytokine-1 in cancer. J Cell Physiol 224: pp. 626-635 CrossRef
29. Bauskin, AR, Brown, DA, Kuffner, T, Johnen, H, Luo, XW, Hunter, M, Breit, SN (2006) Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res 66: pp. 4983-4986 CrossRef
30. Koopmann, J, Buckhaults, P, Brown, DA, Zahurak, ML, Sato, N, Fukushima, N, Sokoll, LJ, Chan, DW, Yeo, CJ, Hruban, RH, Breit, SN, Kinzler, KW, Vogelstein, B, Goggins, M (2004) Serum macrophage inhibitory cytokine 1 as a marker of pancreatic and other periampullary cancers. Clin Cancer Res 10: pp. 2386-2392 CrossRef
31. Koopmann, J, Rosenzweig, CN, Zhang, Z, Canto, MI, Brown, DA, Hunter, M, Yeo, C, Chan, DW, Breit, SN, Goggins, M (2006) Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 12: pp. 442-446 CrossRef
32. Ozkan, H, Demirbas, S, Ibis, M, Akbal, E, Koklu, S (2011) Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases. Pancreatology 11: pp. 295-300 CrossRef
33. Kaur, S, Chakraborty, S, Baine, MJ, Mallya, K, Smith, LM, Sasson, A, Brand, R, Guha, S, Jain, M, Wittel, U, Singh, SK, Batra, SK (2013) Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. PLoS One 8: pp. e55171 CrossRef
34. Wang, XB, Jiang, XR, Yu, XY, Wang, L, He, S, Feng, FY, Guo, LP, Jiang, W, Lu, SH (2014) Macrophage inhibitory factor 1 acts as a potential biomarker in patients with esophageal squamous cell carcinoma and is a target for antibody-based therapy. Cancer Sci 105: pp. 176-185 CrossRef
35. Locker, GY, Hamilton, S, Harris, J, Jessup, JM, Kemeny, N, Macdonald, JS, Somerfield, MR, Hayes, DF, Bast, RC (2006) ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 24: pp. 5313-5327 CrossRef
36. Wiklund, FE, Bennet, AM, Magnusson, PK, Eriksson, UK, Lindmark, F, Wu, L, Yaghoutyfam, N, Marquis, CP, Stattin, P, Pedersen, NL, Adami, HO, Gr枚nberg, H, Breit, SN, Brown, DA (2010) Macrophage inhibitory cytokine-1 (MIC-1/GDF15): a new marker of all-cause mortality. Aging Cell 9: pp. 1057-1064 CrossRef
37. Brown, DA, Hance, KW, Rogers, CJ, Sansbury, LB, Albert, PS, Murphy, G, Laiyemo, AO, Wang, Z, Cross, AJ, Schatzkin, A, Danta, M, Srasuebkul, P, Amin, J, Law, M, Breit, SN, Lanza, E (2012) Serum macrophage inhibitory cytokine-1 (MIC-1/GDF15): a potential screening tool for the prevention of colon cancer?. Cancer Epidemiol Biomarkers Prev 21: pp. 337-346 CrossRef
38. Brown, DA, Stephan, C, Ward, RL, Law, M, Hunter, M, Bauskin, AR, Amin, J, Jung, K, Diamandis, EP, Hampton, GM, Russell, PJ, Giles, GG, Breit, SN (2006) Measurement of serum levels of macrophage inhibitory cytokine 1 combined with prostate-specific antigen improves prostate cancer diagnosis. Clin Cancer Res 12: pp. 89-96 CrossRef
39. Mehta, RS, Song, M, Bezawada, N, Wu, K, Garcia-Albeniz, X, Morikawa, T, Fuchs, CS, Ogino, S, Giovannucci, EL, Chan, AT (2014) A Prospective Study of Macrophage Inhibitory Cytokine-1 (MIC-1/GDF15) and Risk of Colorectal Cancer. J Natl Cancer Inst 106: pp. dju016 CrossRef
40. Staff, AC, Bock, AJ, Becker, C, Kempf, T, Wollert, KC, Davidson, B (2010) Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer. Gynecol Oncol 118: pp. 237-243 CrossRef
41. Skipworth, RJ, Deans, DA, Tan, BH, Sangster, K, Paterson-Brown, S, Brown, DA, Hunter, M, Breit, SN, Ross, JA, Fearon, KC (2010) Plasma MIC-1 correlates with systemic inflammation but is not an independent determinant of nutritional status or survival in oesophago-gastric cancer. Br J Cancer 102: pp. 665-672 CrossRef
42. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/578/prepub - 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
- 出版者：BioMed Central
- ISSN：1471-2407
文摘
Background Macrophage inhibitory cytokine 1 (MIC-1/GDF15) has been identified as a potential novel biomarker for detection of pancreatic cancer (PCa). However, the diagnostic value of serum MIC-1 for pancreatic ductal adenocarcinoma (PDAC), particularly for those at the early stage, and the value for treatment response monitoring have not yet been investigated. Methods MIC-1 expression in tumor tissue was analyzed by RT-PCR from 64 patients with PDAC. Serum MIC-1 levels were detected by ELISA in 1472 participants including PDAC, benign pancreas tumor, chronic pancreatitis and normal controls. The diagnostic performance of MIC-1 was assessed and compared with CA19.9, CEA and CA242, and the value of it as a predictive indicator for therapeutic response and tumor recurrence was also evaluated. Results MIC-1 levels were significantly elevated in PDAC tissues as well as serum samples. The sensitivity of serum MIC-1 for PDAC diagnosis was much higher than that of CA19.9 (65.8% vs. 53.3%) with similar specificities. Furthermore, serum MIC-1 detected 238 out of 377 (63.1%) CA19.9-negative PDAC. Moreover, receiver operating characteristic (ROC) curve analysis also showed that serum MIC-1 had a better performance compared with CA19.9 in distinguishing early-stage PDAC from normal serum with a higher sensitivity (62.5% vs. 25.0% respectively). Notably, serum MIC-1 level was significantly decreased in patients with PDAC after curative resection and returned to elevated levels when tumor relapse occurred. Conclusions Serum MIC-1 is significantly elevated in most PDAC, including those with negative CA19.9 and early stage disease, and thus may serve as a novel diagnostic marker in early diagnosis and postoperative monitoring of PDAC.